

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, November 1, 2022
Alfresa Holdings Corporation

Notice regarding Revisions to the Consolidated Performance Forecast [Prepared on the Basis of Japan's Generally Accepted Accounting Principles (GAAP)]

In view of recent performance trends and other factors, Alfresa Holdings Corporation (the Company) has revised its consolidated performance forecast, announced on October 27, 2022, for the first half of fiscal 2022 (April 1, 2022–March 31, 2023). The revised forecast is as follows.

1. Revised Consolidated Performance Forecast for the First Half (April 1, 2022–September 30, 2022) of Fiscal 2022

	Net sales	Operating income	Ordinary profit	Profit attributable to owners of the parent	Earnings per share of common stock
	¥ Million	¥ Million	¥ Million	¥ Million	Yen
Previous forecast (A)	1,332,000	11,500	12,800	7,900	39.04
Revised forecast (B)	1,332,000	10,100	11,400	7,000	34.59
Change (B-A)	0	(1,400)	(1,400)	(900)	-
Percentage change (%)	0.0	(12.2)	(10.9)	(11.4)	-
(Ref.) Results for the first half of the previous fiscal year (first half of fiscal 2021)	1,288,706	9,117	10,956	6,988	33.02

2. Reason for Revisions of Consolidated Performance Forecast

Since October 28, 2022, as claims on certain of its business partners may become irrecoverable, the Company expects that its operating income, ordinary profit, and profit attributable to owners of the parent will be lower than its previous forecast.

* The above forecast was prepared on the basis of available information at the time of the release of this notice. Actual performance may differ from the forecasted figures due to various factors arising in the future.

About **Alfresa Group**

The Alfresa Group is a leader in the Japanese healthcare industry, which is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.5 trillion for the fiscal year ended March 31, 2022. For more information, please see: <https://www.alfresa.com/eng/>